Pathogenicity of SARS-CoV-2 Omicron.
作者信息
Chu Hin, Yuen Kwok-Yung
机构信息
State Key Laboratory of Emerging Infectious Diseases, Li Ka Shing Faculty of Medicine, Department of Microbiology, Carol Yu Centre for Infection, School of Clinical Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, Pokfulam, China.
Department of Clinical Microbiology and Infection Control, The University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong Province, China.
出版信息
Clin Transl Med. 2022 May;12(5):e880. doi: 10.1002/ctm2.880.
Abstract
摘要
相似文献
1
Pathogenicity of SARS-CoV-2 Omicron.
Clin Transl Med. 2022 May;12(5):e880. doi: 10.1002/ctm2.880.
2
Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant.
Nature. 2022 Mar;603(7902):700-705. doi: 10.1038/s41586-022-04462-1. Epub 2022 Feb 1.
3
Pathogenicity of SARS-CoV-2 Omicron (R346K) variant in Syrian hamsters and its cross-neutralization with different variants of concern.
EBioMedicine. 2022 May;79:103997. doi: 10.1016/j.ebiom.2022.103997. Epub 2022 Apr 8.
4
Spike and nsp6 are key determinants of SARS-CoV-2 Omicron BA.1 attenuation.
Nature. 2023 Mar;615(7950):143-150. doi: 10.1038/s41586-023-05697-2. Epub 2023 Jan 11.
5
Reduced pathogenicity of the SARS-CoV-2 omicron variant in hamsters.
Med. 2022 Apr 8;3(4):262-268.e4. doi: 10.1016/j.medj.2022.03.004. Epub 2022 Mar 17.
6
Real-life Evidence of Lower Lung Virulence in COVID-19 Inpatients Infected with SARS-CoV-2 Omicron Variant Compared to Wild-Type and Delta SARS-CoV-2 Pneumonia.
Lung. 2022 Oct;200(5):573-577. doi: 10.1007/s00408-022-00566-7. Epub 2022 Sep 17.
7
Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron.
Nature. 2022 Mar;603(7902):693-699. doi: 10.1038/s41586-022-04442-5. Epub 2022 Jan 21.
8
SARS-CoV-2 Variants Show a Gradual Declining Pathogenicity and Pro-Inflammatory Cytokine Stimulation, an Increasing Antigenic and Anti-Inflammatory Cytokine Induction, and Rising Structural Protein Instability: A Minimal Number Genome-Based Approach.
Inflammation. 2023 Feb;46(1):297-312. doi: 10.1007/s10753-022-01734-w. Epub 2022 Oct 10.
9
Virological features and pathogenicity of SARS-CoV-2 Omicron BA.2.
Cell Rep Med. 2022 Sep 20;3(9):100743. doi: 10.1016/j.xcrm.2022.100743. Epub 2022 Aug 29.
10
Pathogenicity of SARS-CoV-2 Omicron BA.1.1 in hamsters.
EBioMedicine. 2022 Jun;80:104035. doi: 10.1016/j.ebiom.2022.104035. Epub 2022 Apr 28.
引用本文的文献
1
The potential of long-term wastewater-based surveillance to predict COVID-19 waves peak in Mexico.
Water Environ Res. 2025 May;97(5):e70095. doi: 10.1002/wer.70095.
2
Tight junction protein occludin is an internalization factor for SARS-CoV-2 infection and mediates virus cell-to-cell transmission.
Proc Natl Acad Sci U S A. 2023 Apr 25;120(17):e2218623120. doi: 10.1073/pnas.2218623120. Epub 2023 Apr 17.
3
Chronological changes of viral shedding in adult inpatients with Omicron infection in Shanghai, China.
Front Immunol. 2023 Feb 1;14:1090498. doi: 10.3389/fimmu.2023.1090498. eCollection 2023.
4
Clinical Outcome of Coronavirus Disease 2019 in Patients with Primary Antibody Deficiencies.
Pathogens. 2023 Jan 9;12(1):109. doi: 10.3390/pathogens12010109.
5
Neutralizing antibody titers to Omicron six months after vaccination with BNT162b2 in Colombia.
Front Immunol. 2022 Dec 21;13:1102384. doi: 10.3389/fimmu.2022.1102384. eCollection 2022.
6
An Exploration of Nanoparticle-Based Diagnostic Approaches for Coronaviruses: SARS-CoV-2, SARS-CoV and MERS-CoV.
Nanomaterials (Basel). 2022 Oct 11;12(20):3550. doi: 10.3390/nano12203550.
7
Introduction, Spread and Impact of the SARS-CoV-2 Omicron Variants BA.1 and BA.2 in Cyprus.
Microorganisms. 2022 Aug 23;10(9):1688. doi: 10.3390/microorganisms10091688.
8
Differences Between Omicron Infections and Fever Outpatients: Comparison of Clinical Manifestations and Initial Routine Hematology Indicators.
Infect Drug Resist. 2022 Aug 31;15:5111-5120. doi: 10.2147/IDR.S378990. eCollection 2022.
9
The Omicron Variant BA.1.1 Presents a Lower Pathogenicity than B.1 D614G and Delta Variants in a Feline Model of SARS-CoV-2 Infection.
J Virol. 2022 Sep 14;96(17):e0096122. doi: 10.1128/jvi.00961-22. Epub 2022 Aug 24.
10
Targeting ACLY efficiently inhibits SARS-CoV-2 replication.
Int J Biol Sci. 2022 Jul 11;18(12):4714-4730. doi: 10.7150/ijbs.72709. eCollection 2022.
本文引用的文献
1
Household transmission of SARS-CoV-2 Omicron variant of concern subvariants BA.1 and BA.2 in Denmark.
Nat Commun. 2022 Sep 30;13(1):5760. doi: 10.1038/s41467-022-33498-0.
2
Reduced pathogenicity of the SARS-CoV-2 omicron variant in hamsters.
Med. 2022 Apr 8;3(4):262-268.e4. doi: 10.1016/j.medj.2022.03.004. Epub 2022 Mar 17.
3
Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study.
Lancet. 2022 Apr 2;399(10332):1303-1312. doi: 10.1016/S0140-6736(22)00462-7. Epub 2022 Mar 16.
4
Assessing the clinical severity of the Omicron variant in the Western Cape Province, South Africa, using the diagnostic PCR proxy marker of RdRp target delay to distinguish between Omicron and Delta infections - a survival analysis.
Int J Infect Dis. 2022 May;118:150-154. doi: 10.1016/j.ijid.2022.02.051. Epub 2022 Feb 27.
5
Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant.
Nature. 2022 Mar;603(7902):700-705. doi: 10.1038/s41586-022-04462-1. Epub 2022 Feb 1.
6
Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous SARS-CoV-2 High Transmission Periods - United States, December 2020-January 2022.
MMWR Morb Mortal Wkly Rep. 2022 Jan 28;71(4):146-152. doi: 10.15585/mmwr.mm7104e4.
7
The omicron (B.1.1.529) SARS-CoV-2 variant of concern does not readily infect Syrian hamsters.
Antiviral Res. 2022 Feb;198:105253. doi: 10.1016/j.antiviral.2022.105253. Epub 2022 Jan 21.
8
Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study.
Lancet. 2022 Jan 29;399(10323):437-446. doi: 10.1016/S0140-6736(22)00017-4. Epub 2022 Jan 19.
9
Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron.
Nature. 2022 Mar;603(7902):693-699. doi: 10.1038/s41586-022-04442-5. Epub 2022 Jan 21.
10
SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters.
Nature. 2022 Mar;603(7902):687-692. doi: 10.1038/s41586-022-04441-6. Epub 2022 Jan 21.
Zotero 插件